HEPATIC OSTEODYSTROPHY IN AUTOIMMUNE LIVER DISEASES
- Authors: Prashnova MK1, Raikhelson KL1, Kharitonov AG1, Baranovskiy AY.1
-
Affiliations:
- North-Western State Medical University named after I.I. Mechnikov
- Issue: Vol 7, No 3 (2015)
- Pages: 83-92
- Section: Reviews
- URL: https://journals.rcsi.science/vszgmu/article/view/8510
- DOI: https://doi.org/10.17816/mechnikov20157383-92
- ID: 8510
Cite item
Abstract
Несмотря на несомненные успехи, достигнутые в понимании этиологии и патогенеза аутоиммунных заболеваний печени, остается еще множество нерешенных вопросов. Актуальной проблемой современной медицины являются нарушения костного обмена у данной категории больных. Поздняя диагностика этих осложнений, часто на стадии тяжелого остеопороза с развитием инвалидизирующих переломов, определяет отсутствие своевременного начала терапии, потерю трудоспособности и сложность социальной реабилитации больных, ухудшая прогноз выживаемости.
Full Text
##article.viewOnOriginalSite##About the authors
M K Prashnova
North-Western State Medical University named after I.I. Mechnikov
K L Raikhelson
North-Western State Medical University named after I.I. Mechnikov
A G Kharitonov
North-Western State Medical University named after I.I. Mechnikov
A Yu Baranovskiy
North-Western State Medical University named after I.I. Mechnikov
References
- Рожинская Л. Я. Системный остеопороз: Практическое руководство для врачей.- М.: Издатель Мокеев, 2000.- 196 с.
- O'Neill T.W., Felsenberg D., Varlow J. et al. The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study // J Bone Miner Res. - 1996. - №11. - P. 1010-1018.
- Collier J. Bone disorders in chronic liver disease // Hepatology. - 2007. - Vol.46. - № 4. - P.306-311.
- Nakchbandi I.A., van der Merwe S.W. Current understanding of osteoporosis associated with liver disease // Nat Rev Gastroenterol Hepatol. - 2009. - № 6. - P. 660-670.
- Михайлов Е. Е., Беневоленская Л. И., Мылов Н. М. Распространенность переломов позвоночника в популяционной выборке лиц 50 лет и старше // Вестник травматологии и ортопедии им Н. Н. Приорова. - 1997. - №3. - С. 20-27.
- Lopez-Larramona G., Lucendo A., Gonzalez-Castillo S. et al. Hepatic osteodystrophy: An important matter for consideration in chronic liver disease //World J Hepatol. - 2011. - Vol. 3 - №12. - P. 300 - 307.
- Sinigaglia L., Fargion S., Fracanzani A.L. et al. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload //J Rheumatol. - 1997. - №.24. - P. 1809-1813.
- Malik P., Gasser R.W., Kemmler G. et al. Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study // Alcohol Clin Exp Res. - 2009. - №33. - P. 375-381.
- Goral V., Simsek M., Mete N. Hepatic osteodystrophy and liver cirrhosis // World J Gastroenterol. - 2010. - №16. - P.1639-1643.
- Janes C.H., Dickson E.R., Okazaki R. et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice // J Clin Invest. - 1995. - Vol.95. - № 6. - P. 2581-2586.
- Guichlear M.M., Kendall R., Malinchoc M. et al. Bone mineral density before and after OLT: long term follow-up and predictive factors // Liver Transpl. - 2006. - Vol. 12. - №9. - P.195-200.
- Menon K.V., Angulo P., Weston S. et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression // J Hepatol. - 2001. - Vol. 35. - P. 316-323.
- Guanabens N., Pares A., Ros I. et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis // J. Hepatol. - 2005. - Vol. 42(4). - P. 573-577.
- Angulo P., Gradison G.A., Fong D.G. et al. Bone disease in patients with primary sclerosing cholangitis // Gastroenterology. - 2011. - Vol. 140. - P.180-188.
- Campbell M.S., Lichtenstein G.R., Rhim A.D. et al. Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis // Liver Int. - 2005. - Vol. 25(2). - P. 311-316.
- Angulo P., Therneau T.M., Jorgensen A. et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression // J Hepatol. - 1998. - Vol. 29. - P. 729-735.
- Mounach A., Ouzzif Z., Wariaghli G. et al. Primary biliary cirrhosis and osteoporosis: a case-control study // J Bone Miner Metab. - 2008. - Vol. 2. - P. 379-384.
- Lindor K.D., Janes C.H., Crippin J.S. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? // Hepatology. - 1995. - Vol.21. - P. 389-392.
- Solaymani-Dodaran M., Card T.R., Aithal G.P. et al. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study // Gastroenterology. - 2006. - Vol. 131. - P. 1752-1757.
- Uretmaen S., Gol M., Cimrin D. et al. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women // Eur J Obstet Gynecol Reprod Biol. - 2005. - Vol.123 (1). - P.67-71.
- Hay J.E. Osteoporosis in liver diseases and after liver transplantation // J Hepatol. - 2003. - Vol. 38. - P. 856-865.
- Crosbie O.M., Freaney R., McKenna M.J. et al. Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease // Calcif Tissue Int. - 1999. - Vol. 64. - P. 295-300.
- Guichelaar M.M., Malinchoc M., Sibonga J. et al. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry // Hepatology. - 2002. - Vol. 36. - P. 895-903.
- Пронченко И.А., Ермакова И.П., Мойсюк Я.Г. и др. Костный обмен и минеральная плотность костной ткани поясничных позвонков у женщин с первичным билиарным циррозом до и после ортотопической трансплантации печени // Вестник трансплантологии и искусственных органов. - 2013. -Том XV. - №1. - С. 21-30.
- Guanabens N., Pares A., Alvarez L. et al. Collagen-related markers of bone turnover refl ect the severity of liver fibrosis in patients with primary biliary cirrhosis // J. Bone Miner. Res. -1998. - Vol. 13 (4). - P. 731-738.
- Прашнова М.К., Райхельсон К.Л., Марченко Н.В. Биохимические маркеры костного метаболизма при аутоиммунных заболеваниях печени // Проблемы медицины в современных условиях. Сборник научных трудов по итогам международной научно-практической конференции. - 2014. - С. 66-69.
- Collier J.D., Ninkovic M., Compston J.E. Guidelines on the management of osteoporosis associated with chronic liver disease // Gut. - 2002. - Vol. 50. - Suppl 1. - P. i1-i9.
- Crawford B.A., Labio E.D., Strasser S.I. et al. Vitamin D replacement for cirrhosis-related bone disease // Nat Clin Pract Gastroenterol Hepatol. - 2006. - Vol. 3. - P. 689-699.
- Pares A., Guanabens N. and Rodes J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in PBC // Eur J Gastroenterol Hepatol. - 2005. - Vol. 17(3). - P. 311-315.
- Malham M., Jorgensen S.P., Ott P. et al. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology // World J Gastroenterol. - 2011. - Vol. 17(7). - P. 922-925.
- Smith D.L., Shire N.J., Watts N.B. et al. Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease // J Clin Densitom. - 2006. - Vol. 9. - P. 105-113.
- Nishiguchi S., Shimoi S., Kurooka H. et al. Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis // J Hepatol. - 2001. - Vol. 35. - P. 543-545.
- Iwamoto J., Takeda T. and Sato Y. Effects of vitamin K2 on osteoporosis // Curr Pharm Des. - 2004. - Vol. 10(21). - P. 2557-2576.
- Soylu A.R., Tuglu C., Arikan E et al. The Role of Serum Cytokines in the Pathogenesis of Hepatic Osteodystrophy in Male Cirrhotic Patients // Gastroenterology Research and Practice. - 2012. - Article ID 425079. - P. 6.
- González-Calvin J.L., Mundi J.L., Casado-Caballero F.J. et al. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis // J Clin Endocrinol Metab. - 2009. - Vol. 94. - P. 4844- 4850.
- Bell H., Raknerud N., Falch J.A. et al. Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis // Eur J Endocrinol. - 1995. - Vol.132. - P. 444-449.
- Prince M., Christensen E., Gluud C. Glucocorticosteroids for primary biliary cirrhosis // Cochrane Database Syst Rev. - 2005:CD003778.
- M. Mazzantini, O. Di Munno. Glucocorticoid-induced osteoporosis: 2013 update // Reumatismo. - 2014. - Vol. 66 (1). - P. 144-152.
- Van Staa T.P., Leufkens H.G., Abenhaim L. et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses // Rheumatol. Phys. Med. - 2000. - Vol. 39. - P. 1383-1389.
- Gasser R.W. Cholestasis and metabolic bone disease - a clinical review // Wien Med Wochenschr. - 2008. - Vol. 158. - P. 553-557.
- Kanis J.A., McCloskey E.V., Johansson H. et al. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK // Osteoporos Int. - 2008. - Vol.19. - P. 1395-1408.
- National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis // Washington, DC: National Osteoporosis Foundation. - 2013.
- Pares A., Guanabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment // Clin Liver Dis. - 2008. - Vol. 12. - P. 407-424.
- Zein C.O., Jorgensen R.A., Clarke B. et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial // Hepatology. - 2005. - Vol. 42. - P. 762-771.
- Guanabens N., Pares A., del Rio L. et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis // J Hepatol.- 1992. - Vol.15. - P. 345-349.
- EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. European Association for the Study of the Liver // Journal of Hepatology. - 2009.- Vol. 51. - P. 237-267.
- Lindor K. D., Gershwin M.E., Poupon R. et al. Primary Biliary Cirrhosis // Hepatology. - 2009. - V. 50(1). - P.291-308.
- Bilezikian J.P. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis // Am J Med. - 2009. - Vol.122. - P. S14-21.
- Levy C., Harnois D.M., Angulo P. et al.Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study // Liver Int. - 2005. - Vol. 25. - P. 117-121.
- Hay J.E., Malinchoc M., Dickson E.R. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis // J Hepatol. - 2001/- Vol. 34(2). - 292-298.
- Saag K.G., Shane E., Boonen S. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis // N Engl J Med. - 2007. - Vol. 357. - P. 2028-2039.
- Kinyó Á., Belso N., Nagy N.et al. Strontium ranelate-induced DRESS syndrome with persistent autoimmune hepatitis // Acta Derm Venereol. - 2011. - Vol. 91. - P. 205-206.
- Барановский А.Ю., Райхельсон К.Л., Семенов Н.В. и др. Принципы лечения холестатических заболеваний печени // Лечащий Врач. - 2012. - №7 - С. 43.
- Verma A., Maxwell J.D., Ang L. et al. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis // Osteoporos Int. - 2002. - Vol.13(8). - P. 677-682.
- Ильченко А.А., Коричева Е.С., Дроздов В.Н. Эффективность урсотерапии при желчнокаменной болезни, сопровождающейся дефицитом витамина D и нарушением минеральной плотности костной ткани // Клинические перспективы в гастроэнтерологии, гепатологии. - 2011. - N 1. - С.20-24.
- Dubreuil M., Ruiz-Gaspà S., Guañabens N. et al. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells // Liver Int. - 2013. - Vol. 33(7). - P.1029-1038.